生长板功能调控与身材矮小症的相关研究及治疗进展

莫国生 ,  马云婷 ,  桂宝恒

中国当代儿科杂志 ›› 2026, Vol. 28 ›› Issue (9) : 1150 -1156.

PDF (740KB)
中国当代儿科杂志 ›› 2026, Vol. 28 ›› Issue (9) : 1150 -1156. DOI: 10.7499/j.issn.1008-8830.2605062
综述

生长板功能调控与身材矮小症的相关研究及治疗进展

作者信息 +

Growth plate regulation and short stature: mechanistic insights and therapeutic advances

Author information +
文章历史 +
PDF (757K)

摘要

生长板是长骨纵向生长的关键结构,其功能受全身内分泌、局部旁分泌、细胞外基质结构支持及细胞内信号通路等复杂网络协同调控,生长板调控紊乱可导致身材矮小症(short stature, SS)。目前SS的治疗以各种激素替代方案为主,但疗效存在差异。靶向药物、分子靶向递送及基因治疗等新兴疗法已展现出应用潜力。该文将阐述生长板的结构与功能,归纳其功能紊乱与SS的关联,总结相关研究与治疗进展,为解析SS的分子致病机制、探索精准治疗策略提供参考。

Abstract

The growth plate is the key structure for longitudinal growth of long bones, and its function is coordinated by a complex network of systemic endocrine signals, local paracrine signals, structural support from the extracellular matrix, and intracellular signaling pathways. Dysregulation of this network can lead to short stature (SS). At present, treatment of SS mainly relies on various hormone replacement therapies, but efficacy varies. Emerging approaches, including targeted drugs, molecularly targeted delivery, and gene therapy, have demonstrated potential for clinical application. This review describes the structure and function of the growth plate, summarizes the association between its dysfunction and SS, and outlines related research and therapeutic advances, with the aim of informing studies on the molecular pathogenesis of SS and the exploration of precision treatment strategies.

Graphical abstract

关键词

身材矮小症 / 生长板 / 信号通路 / 治疗

Key words

Short stature / Growth plate / Signaling pathway / Therapy

引用本文

引用格式 ▾
莫国生,马云婷,桂宝恒. 生长板功能调控与身材矮小症的相关研究及治疗进展[J]. 中国当代儿科杂志, 2026, 28(9): 1150-1156 DOI:10.7499/j.issn.1008-8830.2605062

登录浏览全文

4963

注册一个新账户 忘记密码

身材矮小症(short stature, SS)是指在相似生活环境下,个体身高低于同种族、同性别、同年龄正常人群均值的2个标准差或第3百分位数的病理状态[1],中国儿童SS发病率约为3.2%[2]。人类身高由长骨两端生长板的纵向生长所决定。生长板由软骨细胞和细胞外基质(extracellular matrix, ECM)组成,其结构和功能受全身内分泌、局部旁分泌、ECM结构支持及细胞内信号通路等多维网络协同调控,调控紊乱可导致SS[3]。目前,SS治疗以重组人生长激素(recombinant human growth hormone, rhGH)和延缓生长板闭合的药物为主,但部分患者疗效欠佳[4]。新兴的生长板靶向药物、分子靶向递送及基因疗法等治疗策略展现出应用潜力,已成为SS研究的前沿热点[5-7]。本文将阐述生长板的结构与功能,归纳其功能紊乱与SS的关联,总结相关研究与治疗进展,为解析SS的分子致病机制、探索精准治疗策略提供参考。

1 生长板的结构与功能

生长板位于长骨的骺端与干骺端之间,根据其软骨细胞所处时期的差异,依次分为静止区、增殖区、肥大前区、肥大区和临时钙化区。静止区软骨细胞具备干细胞特性,经不对称分裂补充增殖区细胞。增殖区软骨细胞分裂活跃,合成Ⅱ型胶原和聚集蛋白聚糖(aggrecan),维持该区软骨细胞柱状排列。肥大前区软骨细胞停止合成Ⅱ型胶原并启动分化。肥大区软骨细胞体积可增大6~10倍,同时分泌Ⅹ型胶原,诱导ECM钙化。多数软骨细胞在临时钙化区转分化为成骨细胞或骨细胞,同时分泌血管内皮生长因子诱导血管生成,运送破骨细胞清除残余的软骨细胞。ECM由软骨细胞合成并分泌至细胞间隙,具有结构支持作用。生长板通过软骨细胞增殖、分化及ECM合成分泌完成软骨内成骨,实现长骨纵向生长[8-10]。生长板功能紊乱可导致骨骼稳态失衡,引起SS[3]、骨关节炎[11]等疾病。

2 生长板功能调控与SS

生长板功能受时空多维度信号精密调控(图1):内分泌信号通路整体调控其发育与功能;旁分泌信号通路介导邻近软骨细胞间信号转导;ECM提供结构支撑与抗压弹性;细胞内信号通路决定软骨细胞增殖与分化方向。上述信号网络相关基因变异可导致骨骼发育不良及SS。

2.1 内分泌信号通路

内分泌激素如生长激素(growth hormone, GH)、胰岛素样生长因子‑1(insulin‑like growth factor‑1, IGF‑1)、性激素等经血液循环输送至骺端与干骺端,通过ECM扩散至生长板内,与软骨细胞表面相应受体结合,系统性调控软骨细胞增殖、分化、ECM合成及生长板闭合进程。内分泌信号紊乱可导致生长板功能异常或过早闭合,引起SS。

GH与肝细胞生长激素受体(growth hormone receptor, GHR)结合,诱导IGF‑1合成。IGF‑1作用于生长板软骨细胞,激活JAK2‑STAT、MAPK、PI3K‑Akt‑mTOR通路,维持软骨细胞存活并促进其增殖、分化[12]。GH1(编码GH的基因)、GHR、IGF1基因变异分别可导致孤立性GH缺乏症1A型[13]、Laron综合征[14]、IGF‑1缺乏症[15],上述疾病均表现为严重生长迟缓、SS,须行相应替代治疗。

雌激素是青春期骨骼生长的关键调控激素,早期低浓度雌激素可促进长骨生长,晚期高浓度雌激素可诱导生长板闭合,这一双重效应决定了成年身高[16]。雄激素可直接刺激长骨生长,或经芳香化酶转化为雌激素,间接发挥调控作用[17]。性早熟患儿因体内雌激素水平过高,会加速生长板闭合,进而引发SS[16]。

2.2 旁分泌信号通路

生长板软骨细胞分泌印度刺猬蛋白(Indian hedgehog protein, IHH)、甲状旁腺激素相关肽(parathyroid hormone‑related peptide, PTHrP)、成纤维细胞生长因子(fibroblast growth factor, FGF)、C型利尿钠肽(C‑type natriuretic peptide, CNP)、骨形态发生蛋白(bone morphogenetic protein, BMP)及WNT等旁分泌因子,上述因子与邻近软骨细胞膜表面相应受体[如成纤维细胞生长因子受体3(fibroblast growth factor receptor 3, FGFR3)、利尿钠肽受体2(natriuretic peptide receptor B, NPR2)等]发生时空特异性结合,经下游信号转导及交互作用维持生长板稳态。旁分泌信号紊乱可阻碍软骨内成骨,导致骨骼发育异常、SS。

IHH由肥大前区软骨细胞分泌,促进软骨细胞增殖,并诱导静止区软骨细胞表达PTHrP。PTHrP可抑制软骨细胞肥大,同时负反馈抑制IHH表达,二者协同调控软骨细胞增殖与分化[18]。IHH纯合变异导致肢端股骨头发育不良[19],PTHLH(编码PTHrP的基因)变异引起短指症E2型[20],上述患者均伴有SS。

FGFR3表达于增殖区及肥大前区软骨细胞,与FGF结合后,经STAT1通路抑制软骨细胞增殖[21];经MAPK‑ERK通路抑制软骨细胞肥大及ECM合成[22]。FGFR3变异可引起致死性骨发育不良、软骨发育不全及软骨发育不良等多种骨骼发育异常[23]。Chen等[24]首次发现,FGFR3变异可通过热休克蛋白B6‑ERK‑动力相关蛋白1‑铁氧还蛋白1轴抑制生长板软骨细胞自噬并触发铜死亡,该发现作为软骨发育不全的新致病机制,为靶向治疗提供新思路。

CNP及其受体NPR2主要表达于增殖区及肥大前区软骨细胞,二者结合后抑制Raf‑1‑MEK‑ERK信号,促进软骨细胞肥大及ECM合成[25]。NPPC(编码CNP的基因)杂合变异可导致匀称型SS伴小手畸形[26]。NPR2纯合变异引起Maroteaux型肢端肢中发育不全[27]。

BMP(如BMP2)及其受体[如骨形态发生蛋白受体1(bone morphogenetic protein receptor 1, BMPR1)]在增殖区及肥大前区软骨细胞中活性最强,通过Smad1/5/8促进软骨细胞增殖、肥大及ECM合成[28];Smad7则负向调控,防止细胞过度肥大[29]。BMP2杂合变异可导致SS、面部畸形及骨骼异常,伴或不伴心脏异常[30]。

WNT信号通路通过经典与非经典通路协同调控软骨祖细胞与软骨细胞功能。经典WNT通路稳定β‑联蛋白(β‑catenin),抑制SRY盒转录因子9(SRY‑box transcription factor 9, SOX9)表达,维持软骨祖细胞的干细胞特性并促进软骨细胞肥大[31]。编码β‑联蛋白的CTNNB1杂合变异可引起CTNNB1综合征,该病以严重神经发育异常伴生长迟缓为特征[32]。非经典WNT通路调控软骨细胞平面细胞极性与迁移,促进软骨细胞有序排列,形成柱状结构[33]。WNT5A(主要配体WNT5A的编码基因)变异可导致Robinow综合征,患者表现为颅面畸形、SS及生殖器发育异常等[34]。

值得注意的是,旁分泌因子并非独立发挥作用,而是构成复杂交互网络,精准调控软骨细胞增殖与肥大。例如,PTHrP抑制WNT/β‑联蛋白信号通路活性[35];FGFR3抑制IHH表达[36],还可促进BMPR1降解[37];CNP拮抗FGFR3诱导的MAPK过度激活[25]。

2.3 ECM结构支持

ECM主要由胶原蛋白(Ⅱ、Ⅸ、Ⅹ和Ⅺ型)、非胶原蛋白[如软骨寡聚基质蛋白(cartilage oligomeric matrix protein, COMP)]和蛋白聚糖(如aggrecan)组成。ECM主要为软骨细胞提供结构支持,维持其柱状排列。编码ECM组分的基因变异可破坏生长板结构,导致骨骼发育障碍。

胶原蛋白在COMP的协同下形成纤维支架,为软骨内成骨提供结构基础[38]。编码Ⅱ型胶原蛋白的COL2A1变异可引起变异蛋白在内质网错误折叠、蓄积,触发内质网应激,抑制软骨细胞增殖并加速凋亡,导致先天性脊柱骨骺发育不良[39]。COMP变异通过类似机制引起假性软骨发育不全[40]。

Aggrecan通过水合作用形成凝胶基质,为组织提供抗压强度与力学支撑[10]。ACAN(编码Aggrecan的基因)变异可导致Aggrecan型脊椎骨骺端发育不良[41]。

2.4 细胞内信号通路

细胞内信号通路通过转录和转录后调控等机制,介导软骨细胞增殖、分化,其异常是SS的关键分子基础。相关分子主要包括SOX9、Runt相关转录因子2(runt‑related transcription factor 2, RUNX2)等转录因子,以及微小核糖核酸(microRNA, miR)等。

SOX9在静止区、增殖区软骨细胞中高表达,可激活COL2A1、ACAN等ECM相关基因表达,并抑制RUNX2表达和β‑联蛋白信号通路活性,维持软骨细胞增殖,抑制其过早肥大[42]。SOX9杂合变异可导致弯肢发育异常,该疾病表现为长骨弯曲、严重SS及性发育障碍[43]。RUNX2高表达于肥大前区及肥大区软骨细胞,可激活COL10A1、MMP13等肥大软骨细胞标志基因表达,促进软骨细胞肥大与ECM钙化[44]。RUNX2杂合变异引起颅骨锁骨发育不良,患儿表现为囟门迟闭、锁骨发育不全和SS[45]。

miR在转录后水平调控基因表达。比如miR‑433靶向抑制BMPR1A、IHH和RUNX2,负调控软骨细胞增殖与分化[46];miR‑322‑5p通过靶向抑制Smad7,促进BMP2诱导的软骨细胞分化[47]。Liu等[48]发现特发性身材矮小症(idiopathic short stature, ISS)患儿血浆外泌体中miR‑26b‑3p显著上调,抑制AKAP2‑ERK1/2信号通路,影响软骨细胞增殖、肥大,导致生长板功能障碍。

3 SS治疗

SS病因复杂,针对生长板功能失调,临床仍以rhGH单药或联用促性腺激素释放激素类似物(gonadotropin‑releasing hormone agonist, GnRHa)、芳香化酶抑制剂(aromatase inhibitor, AI)等治疗为主,但该类疗法对部分患者疗效有限,且可诱发代谢紊乱、性激素失衡及骨骼受损等远期不良反应。以伏索利肽为代表的信号通路靶向药物、分子靶向递送及基因治疗,可实现精准干预,展现出良好的应用潜力。

3.1 传统药物治疗

rhGH通过刺激IGF‑1生成,促进生长板软骨细胞增殖,适用于GH缺乏症(包括原发性GH缺乏症、颅咽管瘤术后继发性GH缺乏等)、Noonan综合征、ISS等,可改善患儿短期生长速度和成年身高[49]。与rhGH治疗相关的最常见的严重不良反应为颅咽管瘤复发、脊柱侧弯[4]或既往脊柱侧弯加重[50]。

GnRHa通过抑制雌激素分泌,延缓生长板闭合;与rhGH联合干预可改善性早熟、GH缺乏症、小于胎龄儿等患儿的终身高,但GnRHa抑制青春期生理进程,可导致暂时性性腺功能减退、骨量减少及心理适应不良[51]。

AI通过阻断雄激素向雌激素转化,延缓生长板闭合,与rhGH联用治疗青春期SS男孩,其身高改善优于单药,且未见骨骼及生殖功能损害。但AI对青春期前SS患儿疗效有限,治疗前需综合评估[52]。

3.2 靶向药物干预治疗

伏索利肽是治疗软骨发育不全的靶向药物,作为CNP类似物,通过抑制FGFR3下游MAPK的过度激活,解除其对软骨细胞增殖与分化的抑制,恢复生长板功能,且半衰期较天然CNP显著延长。治疗后患儿年生长速度明显改善,主要不良反应为注射部位红斑、肿胀,多属轻中度,不影响骨骼成熟[5]。

英菲格拉替尼是口服选择性FGFR1/2/3酪氨酸激酶抑制剂,直接抑制FGFR3活性,从源头阻断异常信号转导。每日低剂量口服可显著改善软骨发育不全患儿年生长速度及肢体比例,疗效优于伏索利肽。最常见的不良反应为高磷血症,未出现因不良反应而停药者。目前,该药正处于Ⅲ期临床试验阶段[53]。

3.3 分子靶向递送治疗

Yuan等[6]发现,ISS患者血浆外泌体中高表达的ISS相关长链非编码RNA(idiopathic short stature related lncRNA, ISSRL)可抑制生长板软骨细胞增殖与成骨分化。基于该机制,研究团队构建同时负载沉默ISSRL的小干扰核糖核酸与过表达GH的工程化外泌体;经软骨靶向肽修饰后,外泌体可特异性结合软骨Ⅱ型胶原,靶向递送至生长板,解除ISSRL抑制并局部补充GH,在矮小大鼠模型中可有效逆转生长障碍,疗效优于单用小干扰核糖核酸或GH。Tailor等[54]将靶向软骨基质蛋白3的抗体片段与IGF‑1融合,实现IGF‑1向生长板精准递送,促进软骨细胞增殖与分化。相较于传统IGF‑1治疗,该方法可显著提高局部药物浓度、延长作用时间,且避免了肾脏等非靶器官毒性,为生长板靶向治疗提供了更安全高效的选择。

3.4 基因治疗

Sia等[7]采用腺相关病毒载体将GHR递送至Laron综合征模型小鼠的肝细胞中,部分恢复GH‑IGF‑1轴功能,可增加模型小鼠体长,为该病的治疗提供了新思路。Angelozzi等[55]发现,敲除FGFR3上游29 kb处的增强子(-29E)可下调FGFR3表达,显著改善软骨发育不全小鼠的骨骼表型,为该病基因治疗提供了新方向。

3.5 SS治疗的挑战与机遇

新兴疗法的临床应用仍面临诸多挑战:生长板缺乏血管分布且结构致密,大幅降低药物、基因载体的递送效率;腺相关病毒载体难以递送大片段基因序列;软骨细胞分裂导致疗效衰减等,进一步研究应聚焦于提高药物或载体递送效率、延长疗效持久性及加强时空调控精准性等方面。此外,体外生长板类器官的成功构建也为新兴靶向药物筛选和治疗策略开发带来了新机遇[56]。

4 总结与展望

生长板是长骨纵向生长的关键结构,其正常的结构与功能直接决定儿童的终身高。生长板软骨细胞增殖与分化受多维度信号网络时空动态调控,其调控异常可干扰软骨细胞正常增殖、分化,破坏生长板时空有序结构,导致软骨内成骨障碍,可表现为生长减速与SS。

针对生长板功能失调所致的SS,治疗策略正从宏观激素替代向微观分子靶向精准干预转变。传统药物治疗在部分患者中疗效欠佳,且长期应用存在潜在风险。靶向药物、分子靶向递送及基因治疗已在动物实验乃至临床试验中展现出应用潜力,为传统疗法效果不佳者提供了新选择。然而,新兴疗法在药物或载体递送效率、疗效持久性及时空调控精准性等方面仍有待进一步优化完善。

总之,随着生长板信号网络时空动态调控机制的深入解析,以及基因编辑、靶向递送系统的技术革新,SS诊疗模式正由基于临床表型的干预管理,转向基于分子发病机制的病因靶向矫正,这种转变将为SS患儿的精准治疗和远期获益奠定基础。

参考文献

[1]

Storr HL, Freer J, Child J, et al. Assessment of childhood short stature: a GP guide[J]. Br J Gen Pract, 2023, 73(729): 184-186. PMCID: PMC10049590. DOI: 10.3399/bjgp23X732525 .

[2]

Li F, Liu K, Zhao Q, et al. Prevalence of short stature among children in China: a systematic review[J]. Pediatr Investig, 2021, 5(2): 140-147. PMCID: PMC8212717. DOI: 10.1002/ped4.12233 .

[3]

Faienza MF, Chiarito M, Brunetti G, et al. Growth plate gene involvement and isolated short stature[J]. Endocrine, 2021, 71(1): 28-34. DOI: 10.1007/s12020-020-02362-w .

[4]

Maghnie M, Ranke MB, Geffner ME, et al. Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort[J]. J Clin Endocrinol Metab, 2022, 107(12): 3287-3301. PMCID: PMC9693805. DOI: 10.1210/clinem/dgac517 .

[5]

Paton DM. Efficacy of vosoritide in the treatment of achondroplasia[J]. Drugs Today (Barc), 2022, 58(9): 451-456. DOI: 10.1358/dot.2022.58.9.3422313 .

[6]

Yuan J, Wang Y, Huang Y, et al. Investigating novel therapeutic approaches for idiopathic short stature: targeting siRNA and growth hormone delivery to the growth plate using exosome nanoparticles[J]. Adv Sci (Weinh), 2024, 11(24): e2309559. PMCID: PMC11200009. DOI: 10.1002/advs.202309559 .

[7]

Sia KC, Gan SU, Mohd Rodhi SH, et al. First use of gene therapy to treat growth hormone resistant dwarfism in a mouse model[J]. Gene Ther, 2022, 29(6): 346-356. PMCID: PMC9203273. DOI: 10.1038/s41434-022-00313-w .

[8]

Hunziker EB. Growth plate structure and function[J]. Pathol Immunopathol Res, 1988, 7(1-2): 9-13. DOI: 10.1159/000157084 .

[9]

Long JT, Leinroth A, Liao Y, et al. Hypertrophic chondrocytes serve as a reservoir for marrow-associated skeletal stem and progenitor cells, osteoblasts, and adipocytes during skeletal development[J]. Elife, 2022, 11: e76932. PMCID: PMC8893718. DOI: 10.7554/eLife.76932 .

[10]

Bendre A, Ottosson L, Baroncelli M, et al. Growth failure in aggrecan deficiency is due to decreased extracellular matrix and impaired growth plate chondrocyte hypertrophy[J]. Bone, 2025, 200: 117594. DOI: 10.1016/j.bone.2025.117594 .

[11]

Brylka LJ, Alimy AR, Tschaffon-Müller MEA, et al. Piezo1 expression in chondrocytes controls endochondral ossification and osteoarthritis development[J]. Bone Res, 2024, 12(1): 12. PMCID: PMC10891122. DOI: 10.1038/s41413-024-00315-x .

[12]

Sarver DC, Garcia-Diaz J, Saqib M, et al. Tmem263 deletion disrupts the GH/IGF-1 axis and causes dwarfism and impairs skeletal acquisition[J]. Elife, 2024, 12: RP90949. PMCID: PMC10945605. DOI: 10.7554/eLife.90949 .

[13]

Haris B, Mohammed I, Ismail Umlai UK, et al. Severe growth hormone deficiency in an Indian boy caused by a novel 6 kb homozygous deletion spanning the GH1 gene[J]. J Clin Res Pediatr Endocrinol, 2024, 16(2): 229-234. PMCID: PMC11590716. DOI: 10.4274/jcrpe.galenos.2022.2022-5-9 .

[14]

Shabbir RMK, Nalbant G, Zaman Q, et al. A recurrent mutation in growth hormone receptor (GHR) gene underlying laron-type dwarfism in a Pakistani family[J]. Yale J Biol Med, 2023, 96(3): 313-325. PMCID: PMC10524814. DOI: 10.59249/tcaa2040 .

[15]

Giacomozzi C, Martin A, Fernández MC, et al. Novel insulin-like growth factor 1 gene mutation: broadening of the phenotype and implications for insulin resistance[J]. J Clin Endocrinol Metab, 2023, 108(6): 1355-1369. DOI: 10.1210/clinem/dgac738 .

[16]

Weise M, De-Levi S, Barnes KM, et al. Effects of estrogen on growth plate senescence and epiphyseal fusion[J]. Proc Natl Acad Sci U S A, 2001, 98(12): 6871-6876. PMCID: PMC34445. DOI: 10.1073/pnas.121180498 .

[17]

Imre E, Akçay S, Yavuz DG. Aromatase enzyme deficiency in an adult male patient and the effects of estrogen replacement therapy: a rare cause of tall stature[J]. Hormones (Athens), 2025, 24(2): 525-532. DOI: 10.1007/s42000-025-00640-8 .

[18]

Reno PL, Wallace S, Doelp SN, et al. The role of the PTHrP/Ihh feedback loop in the unusual growth plate location in mammalian metatarsals and pisiforms[J]. Dev Dyn, 2025, 254(12): 1307-1324. PMCID: PMC12678681. DOI: 10.1002/dvdy.70013 .

[19]

Saeed T, Bibi N, Ahmad A, et al. A novel biallelic variant in IHH causing acrocapitofemoral dysplasia in a Pakistani family[J]. Mol Genet Genomic Med, 2025, 13(3): e70085. PMCID: PMC11883292. DOI: 10.1002/mgg3.70085 .

[20]

Sun J, Yang N, Xu Z, et al. A novel heterozygous mutation in PTHLH causing autosomal dominant brachydactyly type E complicated with short stature[J]. Mol Genet Genomic Med, 2024, 12(2): e2393. PMCID: PMC10844838. DOI: 10.1002/mgg3.2393 .

[21]

Sahni M, Ambrosetti DC, Mansukhani A, et al. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway[J]. Genes Dev, 1999, 13(11): 1361-1366. PMCID: PMC316762. DOI: 10.1101/gad.13.11.1361 .

[22]

Murakami S, Balmes G, Mckinney S, et al. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype[J]. Genes Dev, 2004, 18(3): 290-305. PMCID: PMC338282. DOI: 10.1101/gad.1179104 .

[23]

顾世立, 应令雯, 常国营, 等. FGFR3基因变异所致疾病的临床特征及基因变异分析[J]. 中国当代儿科杂志, 2025, 27(10): 1259-1265. PMCID: PMC12548657. DOI: 10.7499/j.issn.1008-8830.2504002 .

[24]

Chen J, He D, Yuan C, et al. Fibroblast growth factor receptor 3 mutation promotes HSPB6-mediated cuproptosis in hypochondroplasia by impairing chondrocyte autophagy[J]. J Orthop Translat, 2025, 51: 68-81. PMCID: PMC11847030. DOI: 10.1016/j.jot.2025.01.011 .

[25]

Yasoda A, Komatsu Y, Chusho H, et al. Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway[J]. Nat Med, 2004, 10(1): 80-86. DOI: 10.1038/nm971 .

[26]

Hisado-Oliva A, Ruzafa-Martin A, Sentchordi L, et al. Mutations in C-natriuretic peptide (NPPC): a novel cause of autosomal dominant short stature[J]. Genet Med, 2018, 20(1): 91-97. DOI: 10.1038/gim.2017.66 .

[27]

Badawi S, Varghese DS, Raj A, et al. Unveiling the pathogenic mechanisms of NPR2 missense variants: insights into the genotype-associated severity in acromesomelic dysplasia and short stature[J]. Front Cell Dev Biol, 2023, 11: 1294748. PMCID: PMC10702138. DOI: 10.3389/fcell.2023.1294748 .

[28]

Oichi T, Taniguchi Y, Soma K, et al. Adamts17 is involved in skeletogenesis through modulation of BMP-Smad1/5/8 pathway[J]. Cell Mol Life Sci, 2019, 76(23): 4795-4809. PMCID: PMC11105417. DOI: 10.1007/s00018-019-03188-0 .

[29]

Iwai T, Murai J, Yoshikawa H, et al. Smad7 inhibits chondrocyte differentiation at multiple steps during endochondral bone formation and down-regulates p38 MAPK pathways[J]. J Biol Chem, 2008, 283(40): 27154-27164. DOI: 10.1074/jbc.M801175200 .

[30]

Priestley JRC, Deshwar AR, Murthy H, et al. Monoallelic loss-of-function BMP2 variants result in BMP2-related skeletal dysplasia spectrum[J]. Genet Med, 2023, 25(8): 100863. DOI: 10.1016/j.gim.2023.100863 .

[31]

Akiyama H, Lyons JP, Mori-Akiyama Y, et al. Interactions between Sox9 and beta-catenin control chondrocyte differentiation[J]. Genes Dev, 2004, 18(9): 1072-1087. PMCID: PMC406296. DOI: 10.1101/gad.1171104 .

[32]

Nunes-Xavier CE, Pallarès-Sastre M, Rodríguez-Ramos A, et al. Genotype-phenotype characterization and functional reconstitution of pathogenic β-catenin variants from CTNNB1 syndrome patients[J]. PLoS Genet, 2025, 21(10): e1011907. PMCID: PMC12543288. DOI: 10.1371/journal.pgen.1011907 .

[33]

Gao B, Song H, Bishop K, et al. Wnt signaling gradients establish planar cell polarity by inducing Vangl2 phosphorylation through Ror2[J]. Dev Cell, 2011, 20(2): 163-176. PMCID: PMC3062198. DOI: 10.1016/j.devcel.2011.01.001 .

[34]

Zhu H, Chen Y, Niu Y, et al. A novel variant in WNT5A responsible for Robinow syndrome in a male fetus with limb shortening and agenesis of the penis[J]. Clin Dysmorphol, 2022, 31(2): 71-73. DOI: 10.1097/MCD.0000000000000401 .

[35]

Tong WX, Chen HJ, Huang ZL, et al. PTHrP buffers Wnt/β- catenin activity through a PKC-ζ involved negative feedback loop to maintain articular cartilage homeostasis and attenuate osteoarthritis[J]. J Orthop Translat, 2025, 54: 65-76. PMCID: PMC12304701. DOI: 10.1016/j.jot.2025.03.012 .

[36]

Zhou S, Xie Y, Tang J, et al. FGFR3 deficiency causes multiple chondroma-like lesions by upregulating hedgehog signaling[J]. PLoS Genet, 2015, 11(6): e1005214. PMCID: PMC4474636. DOI: 10.1371/journal.pgen.1005214 .

[37]

Qi H, Jin M, Duan Y, et al. FGFR3 induces degradation of BMP type I receptor to regulate skeletal development[J]. Biochim Biophys Acta Mol Cell Res, 2014, 1843(7): 1237-1247. PMCID: PMC4111238. DOI: 10.1016/j.bbamcr.2014.03.011 .

[38]

Melrose J, Shu C, Whitelock JM, et al. The cartilage extracellular matrix as a transient developmental scaffold for growth plate maturation[J]. Matrix Biol, 2016, 52-54: 363-383. DOI: 10.1016/j.matbio.2016.01.008 .

[39]

Fan L, Ji L, Xu Y, et al. A novel mutation c.3392G>T of COL2A1 causes spondyloepiphyseal dysplasia congenital by affecting pre-mRNA splicing[J]. Front Genet, 2022, 13: 827560. PMCID: PMC9174977. DOI: 10.3389/fgene.2022.827560 .

[40]

Zhou L, Chen J, Liu Q, et al. Case report: whole-exome sequencing identified two novel COMP variants causing pseudoachondroplasia[J]. Front Endocrinol (Lausanne), 2023, 14: 1267946. PMCID: PMC10702128. DOI: 10.3389/fendo.2023.1267946 .

[41]

Ahmed HA, Elhossini R, Aglan M, et al. Aggrecan-related bone disorders; a novel heterozygous ACAN variant associated with spondyloepimetaphyseal dysplasia expanding the phenotypic spectrum and review of literature[J]. J Genet Eng Biotechnol, 2024, 22(1): 100341. PMCID: PMC10860877. DOI: 10.1016/j.jgeb.2023.100341 .

[42]

Dy P, Wang W, Bhattaram P, et al. Sox9 directs hypertrophic maturation and blocks osteoblast differentiation of growth plate chondrocytes[J]. Dev Cell, 2012, 22(3): 597-609. PMCID: PMC3306603. DOI: 10.1016/j.devcel.2011.12.024 .

[43]

Wang L, Liu Z, Zhao S, et al. Variants in the SOX9 transactivation middle domain induce axial skeleton dysplasia and scoliosis[J]. Proc Natl Acad Sci U S A, 2025, 122(4): e2313978121. PMCID: PMC11789016. DOI: 10.1073/pnas.2313978121 .

[44]

Rashid H, Chen H, Javed A. Runx2 is required for hypertrophic chondrocyte mediated degradation of cartilage matrix during endochondral ossification[J]. Matrix Biol Plus, 2021, 12: 100088. PMCID: PMC8586806. DOI: 10.1016/j.mbplus.2021.100088 .

[45]

Zhang Y, Duan X. A novel 90-kbp deletion of RUNX2 associated with cleidocranial dysplasia[J]. Genes (Basel), 2022, 13(7): 1128. PMCID: PMC9322484. DOI: 10.3390/genes13071128 .

[46]

Thakore P, Smith SS, Karki S, et al. miR-433 targets BMP and Indian hedgehog signaling to coordinate murine postnatal growth plate dynamics[J]. J Bone Miner Res, 2026, 41(5): 551-564. PMCID: PMC13078589. DOI: 10.1093/jbmr/zjaf182 .

[47]

Zeng Y, Du C, Xiao P, et al. Sox9-increased miR-322-5p facilitates BMP2-induced chondrogenic differentiation by targeting Smad7 in mesenchymal stem cells[J]. Stem Cells Int, 2021, 2021: 9778207. PMCID: PMC8589527. DOI: 10.1155/2021/9778207 .

[48]

Liu X, Yuan J, Wu Z, et al. Plasma exosome miRNA-26b-3p derived from idiopathic short stature impairs longitudinal bone growth via the AKAP2/ERK1/2 axis[J]. J Nanobiotechnology, 2023, 21(1): 94. PMCID: PMC10022307. DOI: 10.1186/s12951-023-01849-8 .

[49]

Danowitz M, Grimberg A. Clinical indications for growth hormone therapy[J]. Adv Pediatr, 2022, 69(1): 203-217. PMCID: PMC9754707. DOI: 10.1016/j.yapd.2022.03.005 .

[50]

Ziv-Baran T, Modan-Moses D, Zacay G, et al. Growth hormone treatment and the risk of adolescent scoliosis: a large matched cohort study[J]. Acta Paediatr, 2023, 112(6): 1240-1248. DOI: 10.1111/apa.16749 .

[51]

Allen NG, Krishna KB, Lee PA. Use of gonadotropin-releasing hormone analogs in children[J]. Curr Opin Pediatr, 2021, 33(4): 442-448. DOI: 10.1097/MOP.0000000000001026 .

[52]

Zhang Y, Yuan X, Mccormick K, et al. The efficacy and safety of rhGH treatment combined with letrozole/GnRHa in adolescent boys[J]. BMC Pediatr, 2025, 25(1): 59. PMCID: PMC11761712. DOI: 10.1186/s12887-025-05408-y .

[53]

Rico-Llanos G, Czyrek AA, Krejci P. Oral infigratinib therapy in children with achondroplasia[J]. N Engl J Med, 2025, 392(23): 2388. DOI: 10.1056/NEJMc2504219 .

[54]

Tailor K, van Ree J, Stowe T, et al. Efficacy of cartilage-targeted IGF-1 in a mouse model of growth hormone insensitivity[J]. Front Endocrinol (Lausanne), 2025, 15: 1523931. PMCID: PMC11756323. DOI: 10.3389/fendo.2024.1523931 .

[55]

Angelozzi M, Molin A, Karvande A, et al. Fgfr3 enhancer deletion markedly improves all skeletal features in a mouse model of achondroplasia[J]. J Clin Invest, 2025, 135(2): e184929. PMCID: PMC11735107. DOI: 10.1172/jci184929 .

[56]

Wang X, Li P, Muselmani MN, et al. Construction of growth plate organoids via a layered induction based in vitro 3D cultivation system[J]. Biomater Adv, 2026, 183: 214742. DOI: 10.1016/j.bioadv.2026.214742 .

基金资助

广西八桂青年拔尖人才培养项目(2025212)

广西十百千人才工程第二层次人选专项(2021186)

中央高水平医院临床科研专项重点培育计划项目(2022-PUMCH-C-033)

中华国际医学交流基金会科研基金资助项目(Z-2019-41-2303)

AI Summary AI Mindmap
PDF (740KB)

120

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉